The Oncology Institute (TOI)
(Delayed Data from NSDQ)
$1.12 USD
+0.06 (5.66%)
Updated May 1, 2024 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for The Oncology Institute, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 324 | 252 | 203 | 0 | 0 |
Cost Of Goods | 265 | 200 | 162 | 0 | 0 |
Gross Profit | 60 | 52 | 41 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 137 | 134 | 87 | 1 | 0 |
Income After Depreciation & Amortization | -77 | -82 | -46 | -1 | 0 |
Non-Operating Income | 1 | 86 | 35 | 0 | 0 |
Interest Expense | 7 | 4 | 0 | 0 | 0 |
Pretax Income | -83 | 0 | -12 | 0 | 0 |
Income Taxes | 0 | 0 | -1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -83 | 0 | -11 | 0 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -83 | 0 | -11 | 0 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -51 | -66 | -42 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 26 | 16 | 3 | 0 | 0 |
Income After Depreciation & Amortization | -77 | -82 | -46 | -1 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.75 | 80.61 | 66.23 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.69 | -0.40 | 0.25 | NA | NA |
Diluted Net EPS (GAAP) | -0.92 | -0.21 | -0.16 | -0.08 | NA |
Fiscal Year end for The Oncology Institute, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 85.79 | 82.04 | 80.22 | 76.19 |
Cost Of Goods | NA | 71.41 | 66.06 | 65.11 | 62.09 |
Gross Profit | NA | 14.38 | 15.98 | 15.12 | 14.10 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 29.67 | 29.91 | 30.06 | 46.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -15.29 | -13.93 | -14.94 | -32.87 |
Non-Operating Income | NA | -1.84 | -0.66 | 0.81 | 5.56 |
Interest Expense | NA | -1.24 | 2.70 | 2.67 | 2.65 |
Pretax Income | NA | -19.07 | -17.28 | -16.80 | -29.95 |
Income Taxes | NA | -0.31 | 0.14 | 0.10 | 0.04 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -18.75 | -17.42 | -16.90 | -30.00 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -18.75 | -17.42 | -16.90 | -30.00 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 73.47 | 73.47 | 74.12 | 73.45 |
Diluted EPS Before Non-Recurring Items | NA | -0.21 | -0.19 | -0.19 | -0.10 |
Diluted Net EPS (GAAP) | NA | -0.21 | -0.19 | -0.19 | -0.33 |